Latest News
ASCO and EHA highlights in myeloma and AL amyloidosis
The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which was held from 29 to 31 May 2020. Two weeks later, the 25th edition of the European Hematology Association’s annual…
Watch the webinar on ASH 2019 highlights held yesterday by Myeloma Patients Europe (MPE)
Myeloma Patients Europe (MPE) held a webinar yesterday on ASH 2019 myeloma and AL amyloidosis highlights with the aim of reviewing the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in December 2019.
MPE webinar on ASH 2019 myeloma and AL amyloidosis highlights
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in December 2019.
ASH 2019 myeloma highlights
More than 900 myeloma abstracts (posters and oral sessions) were presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that was held from 7 to 10 December 2019 in Orlando, Florida, USA. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most…
Myeloma ASH 2019 preview
More than 900 myeloma abstracts (posters and oral sessions) will be presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that will be held from 7 to 10 December 2019 in Orlando, Florida, USA.
ASCO 2019 – Lenalidomide reduces risk that smoldering myeloma will progress to myeloma in high risk patients
The phase II/III E3A06 randomized clinical trial found that lenalidomide (Revlimid) significantly reduces the risk of smoldering multiple myeloma (SMM) — a precancerous condition — from progressing to cancer in patients at moderate or high-risk. Organ damage is typically seen in myeloma, which is a way to differentiate it from SMM. At three years,…
ASH 2018 highlights in myeloma
Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2018.